http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102015020878-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36d8e92ef585421448fef0bf29ae1f0b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| filingDate | 2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc277788b86938ada1671ab1bedc7d3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d34e5311772dd87bf95fd367f32bdae7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62143955f18a4b6996f4dbef236a6354 |
| publicationDate | 2017-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102015020878-A2 |
| titleOfInvention | nasal testosterone pharmaceutical formulation and packet-shaped unit nasal device kit for testosterone monodose application |
| abstract | Summary nasal testosterone pharmaceutical formulation and packet-shaped kit of unit nasal devices for testosterone monodose application. It is a nasal pharmaceutical formulation of testosterone and a set of devices, constituting a packaged pharmaceutical kit for the administration of nasal testosterone, formed from a plurality of therapeutically measured single dose delivery devices. . The set of devices comprising the pharmaceutical kit is characterized by a set of individual devices (1) containing low viscosity, high viscosity micronized testosterone-based gel formulation to provide a patient, whether female or male, precisely measured and physiologically appropriate unit doses of testosterone. After use, the device is immediately discarded by the user, with no residual hormone losses even when administered via the nasal route, due to the high viscosity of the formulation, which, combined with the air pumping system, ensures the release of the device. of virtually all of its content. Each device is provided with a hollow chamber (2), where the medicine is packaged, and an air column area that acts as a plunger to expel the volume of medicine contained in the chamber (2). expulsion air chamber (3) supplies user-pressurized air into the hollow chamber (2), which acts as compressed air in the face of passing through the neck (6) provided between the hollow chamber (2) and the inner tube (3). Tearing lines (8 - 9 - 12) are provided to facilitate the removal of each device from the pack for use. 1/1 1/1 |
| priorityDate | 2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.